Get the Stockscreener App
1.38
1.43%
-0.02
After Hours:
1.38
Evogene Ltd stock is traded at $1.38, with a volume of 27,940.
It is down -1.43% in the last 24 hours and down -6.76% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
See More
Previous Close:
$1.40
Open:
$1.38
24h Volume:
27,940
Relative Volume:
0.70
Market Cap:
$9.38M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-2.6038
EPS:
-0.53
Net Cash Flow:
$-22.36M
1W Performance:
-2.15%
1M Performance:
-6.76%
6M Performance:
-52.08%
1Y Performance:
-82.09%
1-Day Range:
$1.365
$1.4419
1-Week Range:
$1.365
$1.49
52-Week Range:
$1.20
$8.996
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.38 | 9.38M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene Ltd. Earnings Call: Growth Amid Challenges - TipRanks
Evogene Ltd. (NASDAQ:EVGN) Q4 2024 Earnings Call Transcript - Insider Monkey
StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN) - Defense World
Evogene price target lowered to $6 from $11.25 at Alliance Global Partners - TipRanks
Evogene: Q4 Earnings Snapshot - Barchart
Evogene Ltd to Host Earnings Call - ACCESS Newswire
Evogene Ltd (EVGN) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 22.1% in February - Defense World
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025 - StreetInsider.com
Evogene Ltd. Reports Revenue Growth and Strategic Focus - TipRanks
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results - The Malaysian Reserve
Earnings call transcript: Evogene Q4 2024 beats EPS forecast, misses revenue - Investing.com
Evogene Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Evogene reports Q4 EPS 6c vs. ($1.30) last year - TipRanks
Evogene reports Q4 revenue miss, shares slip By Investing.com - Investing.com South Africa
Evogene reports Q4 revenue miss, shares slip - Investing.com
Evogene earnings beat by $0.66, revenue fell short of estimates - Investing.com India
SEC Form 424B3 filed by Evogene Ltd - Quantisnow
Can This Biotech Expert Transform Evogene's AI Drug Discovery Future? - StockTitan
Evogene (TSE:EVGN) Given New C$3.00 Price Target at Desjardins - Defense World
Evogene Ltd expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Evogene (NASDAQ:EVGN) Now Covered by StockNews.com - Defense World
Evogene Ltd. to Host Earnings Call - ACCESS Newswire
Evogene (EVGN) Projected to Post Quarterly Earnings on Thursday - Defense World
StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN) - Armenian Reporter
Evogene Schedules Fourth Quarter 2024 Financial Results Release - Krishak Jagat English
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease - Nasdaq
Evogene Shareholders Approve Key Proposal in Special Meeting - TipRanks
Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com - Armenian Reporter
Evogene Ltd. Reschedules Special General Meeting Due to Lack of Quorum - TipRanks
Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World
United States Agricultural Biologicals Market Competition - GlobeNewswire
United States Agricultural Biologicals Market Competition and Forecasts 2024-2029, Competitive Analysis of BASF, Syngenta Crop Protection, Bayer, Evogene ,Vegalab Inc. - Yahoo Finance
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting - GuruFocus.com
Monsanto Expands Agreement with Israel’s Evogene - Agribusiness Global
Higher R&D costs lead Evogene to loss - גלובס
Evogene Ltd. Announces Conclusion of Employment of Eyal Ronen as Executive Vice President of Business Development, Effective March 4, 2025 - Marketscreener.com
Evogene Announces Management Restructuring - TipRanks
Evogene Announces Special General Meeting to Approve Share Options for CEO - TipRanks
Lavie Bio Announces Expansion of its Bio-Inoculant Product for S - GuruFocus.com
Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com - Defense World
N2OFF (NASDAQ:NITO) and Evogene (NASDAQ:EVGN) Head-To-Head Review - Defense World
Evogene Ltd. (NASDAQ:EVGN) Position Lessened by BNP Paribas Financial Markets - Defense World
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):